drugset / Trial / NCT05931380

A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

NCT05931380

Phase 3 Completed 238 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.

Timeline

Start
2023-07-31
Primary completion
2025-06-19
Completion
2025-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Orforglipron Small molecule 6 mg Oral
Subject Orforglipron Small molecule 12 mg Oral
Subject Orforglipron Small molecule 36 mg Oral

Indications